Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia
Stopped Following a pre-specified interim analysis and Data Monitoring Committee recommendation due to insufficient level of efficacy
Conditions
Interventions
- DRUG: AVE1625
- DRUG: placebo
Sponsor
Sanofi